Newsroom

Sorted by: Latest

-

Semtech Hosts LoRa® Ecosystem Forum at IOTE 2026

CAMARILLO, Calif.--(BUSINESS WIRE)--Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things (“IoT”) devices worldwide, will host the LoRa® Global Ecosystem Forum at the 2026 International Internet of Things Exhibition (IOTE), taking place at the Shenzhen World Exhibition & Convention Center (Bao’an District) from Aug. 26-28. The company is exhibiting in Hall 10, Booth #10C51. T...
-

Interactive Brokers Announces Strategic Collaboration with Daol Investment & Securities

GREENWICH, Conn.--(BUSINESS WIRE)--Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced a strategic collaboration with Daol Investment & Securities to provide eligible Korean investors with cost-effective access to global equities through Daol's platform, supported by IBKR's advanced trading infrastructure. The collaboration highlights Interactive Brokers' strength as a provider of brokerage technology and white-label solutions for introducing brokers worldwide. B...
-

Celltrion amplia il portafoglio Omlyclo® in Europa con il lancio del dosaggio da 300 mg

INCHEON, Corea del Sud--(BUSINESS WIRE)--Celltrion (KRX: 068270) oggi ha annunciato il lancio del dosaggio da 300 mg di Omlyclo® (omalizumab), un trattamento per l'orticaria cronica spontanea e l'asma allergica, in Europa.1 Con l'aggiunta del dosaggio da 300 mg, Celltrion ha ampliato il suo portafoglio di Omlyclo® per includere diversi dosaggi e dispositivi destinati ai pazienti, ai professionisti sanitari e alle strutture sanitarie. A seguito del lancio europeo di Omlyclo® da 75 mg e 150 mg al...
-

Celltrion amplía la gama de Omlyclo® en Europa con el lanzamiento de la dosis de 300 mg

INCHEON, Corea del Sur--(BUSINESS WIRE)--Celltrion (KRX: 068270) acaba de anunciar el lanzamiento en Europa de la dosis de 300 mg de Omlyclo® (omalizumab), tratamiento para la urticaria crónica espontánea y el asma alérgica.1 Con la incorporación de la dosis de 300 mg, Celltrion ha extendido su gama de productos Omlyclo® para poder ofrecer así múltiples dosis y formatos de dispositivos a pacientes, profesionales sanitarios e instituciones sanitarias. Después de la presentación en Europa de Omly...
-

Celltrion erweitert das Omlyclo® -Portfolio in Europa mit der Einführung der 300-mg-Stärke

INCHEON, Südkorea--(BUSINESS WIRE)--Celltrion (KRX: 068270) gab heute die Markteinführung der 300-mg-Dosierung von Omlyclo® (Omalizumab), einem Medikament zur Behandlung von chronischer spontaner Urtikaria und allergischem Asthma, in Europa bekannt.1 Mit der Einführung der 300-mg-Dosierung hat Celltrion sein Omlyclo®-Portfolio um verschiedene Dosierungen und Darreichungsformen für Patienten, medizinisches Fachpersonal und Gesundheitseinrichtungen erweitert. Nach der Markteinführung von Omlyclo®...
-

Celltrion élargit sa gamme Omlyclo® en Europe avec le lancement d'un dosage de 300 mg

INCHEON, Corée du Sud--(BUSINESS WIRE)--Celltrion (KRX : 068270) a annoncé aujourd’hui le lancement en Europe de la dosologie de 300 mg d’Omlyclo® (omalizumab), un traitement contre l’urticaire chronique spontanée et l’asthme allergique.1 Avec l’ajout de cette dosologie de 300 mg, Celltrion a élargi sa gamme Omlyclo® afin d’inclure plusieurs dosages et formats de conditionnement destinés aux patients, aux professionnels de santé et aux établissements de soins. Après le lancement européen d’Omly...
-

Celltrion breidt de Omlyclo®-portfolio in Europa uit met de lancering van de 300 mg sterkte

INCHEON, Zuid-Korea--(BUSINESS WIRE)--Celltrion (KRX: 068270) kondigde vandaag de lancering aan van de 300 mg sterkte van Omlyclo® (omalizumab), een behandeling tegen chronische spontane urticaria (netelroos) en allergische astma, in Europa.1 Met de toevoeging van de 300 mg sterkte heeft Celltrion zijn Omlyclo®-portfolio uitgebreid om meerdere dosissterktes en hulpmiddelpresentaties op te nemen voor patiënten, gezondheidszorgprofessionals en gezondheidszorginstellingen. Na de Europease lancerin...
-

WM Announces Cash Dividend

HOUSTON--(BUSINESS WIRE)--WM (NYSE: WM) today announced the declaration of a quarterly cash dividend of $0.945 per share payable September 25, 2026, to stockholders of record on September 11, 2026. ABOUT WM WM (WM.com) is North America's leading provider of comprehensive environmental solutions. Previously known as Waste Management and based in Houston, Texas, WM is driven by commitments to put people first and achieve success with integrity. WM, through its subsidiaries, provides collection, r...
-

Hawk Fire: U-Haul Offers Disaster Relief to Reno Area Evacuees

RENO, Nev.--(BUSINESS WIRE)--Four U-Haul® facilities are offering 30 days of free self-storage and U-Box® container use to residents affected by the Hawk Fire burning northwest of Reno. The human-caused wildfire has burned more than 15,000 acres and prompted at least 42,000 evacuations, according to reports. Containment remains at 0% as of Monday. While certain areas along Interstate 80 have been deemed safe for residents to return, other families remain away from home or are preparing to leave...
-

Singapore CFO Business Optimism Falls 34 Points, the Sharpest Decline Across Nine Markets

SINGAPORE--(BUSINESS WIRE)--Business optimism among Singapore CFOs fell 34 percentage points year over year, from 93% in late 2025 to 59% in 2026, the largest decline across the nine markets surveyed by Kyriba. At the same time, only 16% of Singapore respondents say their organisations can quantify financial risk exposure in real time or near real time. The findings reveal a widening gap between awareness of risk and the ability to assess its financial impact quickly enough to respond. The find...